Osteopontin splice variants are differential predictors of breast cancer treatment responses

BMC Cancer

Table 1 Patient characteristics

		n	%
T	0	1	0.8
	1	59	49.6
	2	33	27.7
	3	6	5.0
	undefined	20	16.8
N	0	58	48.7
	1	14	11.8
	2	16	13.4
	3	11	9.2
	undefined	20	16.8
grade	1	36	30.3
	2	65	54.6
	3	18	15.1
Her2	low	69	58.0
	high	29	24.4
	undefined	21	17.6
PR	-	64	53.8
	+	54	45.4
	undefined	1	0.8
ER	-	59	49.6
	+	59	49.6
	undefined	1	0.8
BRCA-1	wild type	52	43.7
	mutant	26	21.8
	undefined	41	34.5
familial	no	44	37.0
	yes	40	33.6
	undefined	35	29.4
chemotherapy	AC 4 courses every 21 days, CMF 6 courses every 28 days	34	28.6
	CMF 6 courses every 28 days	55	46.2
	no	30	25.2
radiation therapy	chest (50 Gy; Mon-Fri 2 Gy)	41	34.5
	chest/axilla (50 Gy; Mon-Fri 2 Gy)	31	26.1
	no	47	39.5
hormone treatment	no	54	45.4
	tamoxifen	62	52.1

The patient populations are described according to diverse clinical variables. CMF cyclophosphamide, methotrexate, fluorouracil, AC cyclophosphamide, doxorubicin

ISSN: 1471-2407